Posted by Michael Wonder on 10 Dec 2018
U.S. FDA grants fast track designation to Asana BioSciences’ oral dual JAK-SYK inhibitor, ASN002, for the treatment of atopic dermatitis
10 December 2018 - Asana BioSciences announced today that the U.S. FDA has granted fast track designation to Asana’s investigational oral Janus Kinase and Spleen Tyrosine Kinase dual inhibitor ASN002 for the treatment of moderate-to-severe atopic dermatitis.
ASN002 is currently being evaluated in moderate-to-severe atopic dermatitis in the Phase 2b RADIANT Study (Relief from Atopic DermatitIs with JAK and SYK INhibiTion - NCT03654755). It is also being evaluated in a Phase 2 trial in patients with severe chronic hand eczema (NCT03728504).
